Late Drug-eluting Stent Thrombosis and Erythropoietin: Cause and Effect?

Heart Lung and Circulation

Volumn 16, Issue 4, 2007, Pages 305-307

  Gladding, P A ^a   Webster, M W ^b   Kay, P ^c  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

Erythropoietin; Late stent thrombosis; Myocardial infarction; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; RAPAMYCIN;

ADULT; ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG DOSE INCREASE; DRUG ELUTING STENT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOSIS;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; HUMANS; MALE; REOPERATION; SIROLIMUS; STENTS;

EID: 34347337591     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.01.002     Document Type: Article

References (26)

1. Honda Y., and Fitzgerald P.J. Stent thrombosis: an issue revisited in a changing world. Circulation 108 1 (2003) 2-5
2. Virmani R., Farb A., Guagliumi G., and Kolodgie F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15 6 (2004) 313-318
3. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., Suddath W.O., Weissman N.J., Torguson R., Kent K.M., Pichard A.D., Satler L.F., Waksman R., and Serruys P.W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 9444 (2004) 1519-1521
4. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 2 (2005) 231-236
5. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 12 (2006) 2584-2591
6. Manolis A.S., Tzeis S., Triantafyllou K., Michaelidis J., Pyrros I., Sakellaris N., Kranidis A., and Melita H. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 5 5 (2005) 355-375
7. Lowe G.D., Rumley A., Whincup P.H., and Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2 4 (2002) 429-439
8. Tefferi A., and Spivak J.L. Polycythemia vera: scientific advances and current practice. Semin Hematol 42 4 (2005) 206-220
9. Dhar R., Stout C.W., Link M.S., Homoud M.K., Weinstock J., and Estes III N.A. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 80 10 (2005) 1307-1315
10. Clyne N., Berglund B., and Egberg N. Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Thromb Res 79 1 (1995) 125-129
11. Fuste B., Serradell M., Escolar G., Cases A., Mazzara R., Castillo R., Ordinas A., and Diaz-Ricart M. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 88 4 (2002) 678-685
12. Taylor J.E., McLaren M., Henderson I.S., Belch J.J., and Stewart W.K. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 7 3 (1992) 235-239
13. Malyszko J., Malyszko J.S., Borawski J., Rydzewski A., Kalinowski M., Azzadin A., Mysliwiec M., and Buczko W. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 77 2 (1995) 133-143
14. Stohlawetz P.J., Dzirlo L., Hergovich N., Lackner E., Mensik C., Eichler H.G., Kabrna E., Geissler K., and Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 9 (2000) 2983-2989
15. Sharpe P.C., Desai Z.R., and Morris T.C. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol 47 2 (1994) 159-161
16. Wirtz J.J., van Esser J.W., Hamulyak K., Leunissen K.M., and van Hooff J.P. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 38 5 (1992) 277-282
17. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., Doni M., Mengozzi M., Tonelli R., Ghezzi P., Coleman T., Brines M., Cerami A., and Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 102 6 (2005) 2046-2051
18. Joyeux-Faure M., Godin-Ribuot D., and Ribuot C. Erythropoietin and myocardial protection: what's new?. Fundam Clin Pharmacol 19 4 (2005) 439-446
19. Smith K.J., Bleyer A.J., Little W.C., and Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 59 3 (2003) 538-548
20. Lee P.J., and Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev 13 2 (2005) 80-86
21. Arsenian M.A. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 33 5 (1991) 299-311
22. Kleikamp G., Schnepper U., and Korfer R. Coronary artery and aortic valve disease as a long-term sequel of mediastinal and thoracic irradiation. Thorac Cardiovasc Surg 45 1 (1997) 27-31
23. Teirstein P., and Reilly J.P. Late stent thrombosis in brachytherapy: the role of long-term antiplatelet therapy. J Invasive Cardiol 14 3 (2002) 109-114
24. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 72 6 Suppl (1994) S36-S43
25. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., and Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 20 (2006) 2071-2084
26. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., and Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 20 (2006) 2085-2098